AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer

Wednesday, 11 September 2013

AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD, today announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.

WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumour cells to divide without undergoing the normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of MK-1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone.

Under the terms of the agreement, AstraZeneca will pay Merck a $50 million upfront fee. In addition Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. AstraZeneca will be responsible for all future clinical development, manufacturing and marketing.

“MK-1775 is a strong addition to AstraZeneca’s growing oncology pipeline, which already includes a number of inhibitors of the DNA damage response,” said Susan Galbraith, Head of AstraZeneca’s Oncology Innovative Medicines Unit. “The compound has demonstrated encouraging clinical efficacy data and we intend to study it in a range of cancer types where there is a high unmet medical need.”

“Merck is committed to advancing potentially meaningful therapeutic options promptly for patients with cancer,” said Iain D. Dukes, senior vice president and head of licensing and external scientific affairs at Merck. “We are pleased to enter this agreement with AstraZeneca to realise the potential of MK-1775 while we focus on advancing our later stage oncology programs, MK-3475 and vintafolide.”

The agreement is contingent on expiration or termination of the waiting period under the Hart Scott-Rodino Antitrust Improvement Act.


About MK-1775

WEE1 is a cell cycle checkpoint protein regulator. Preclinical data indicate that disruption of WEE1 may enhance the cell killing effects of some anticancer agents. MK-1775 is an investigational orally available inhibitor of the cell cycle checkpoint protein WEE1. MK-1775 is being evaluated in Phase IIa clinical trials for the treatment of patients with P53-deficient ovarian cancer.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook and YouTube.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:


Media Enquiries    
Esra Erkal-Paler (UK/Global) +44 20 7604 8030
Vanessa Rhodes (UK/Global) +44 20 7604 8037
Ayesha Bharmal (UK/Global)
+44 20 7604 8034
Michele Meixell
(US) +1 302 885 6351
Jacob Lund
(Sweden) +46 8 553 260 20


Investor Enquiries      
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Colleen Proctor +1 302 886 1842 mob: +1 302 357 4882
Anthony Brown +44 20 7604 8067 mob: +44 7585 404943
Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729



  • Corporate and financial
  • Partnering